WO2004105748A1 - アミノ酸組成物及び補液 - Google Patents
アミノ酸組成物及び補液 Download PDFInfo
- Publication number
- WO2004105748A1 WO2004105748A1 PCT/JP2004/007850 JP2004007850W WO2004105748A1 WO 2004105748 A1 WO2004105748 A1 WO 2004105748A1 JP 2004007850 W JP2004007850 W JP 2004007850W WO 2004105748 A1 WO2004105748 A1 WO 2004105748A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mol
- less
- amino acid
- alanine
- proline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 68
- 238000002637 fluid replacement therapy Methods 0.000 title 1
- 229940024606 amino acid Drugs 0.000 claims abstract description 68
- 235000001014 amino acid Nutrition 0.000 claims abstract description 68
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 66
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 39
- 239000004471 Glycine Substances 0.000 claims abstract description 33
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 33
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000004472 Lysine Substances 0.000 claims abstract description 33
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 33
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000004279 alanine Nutrition 0.000 claims abstract description 33
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000004473 Threonine Substances 0.000 claims abstract description 32
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 32
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 31
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 31
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 31
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 31
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960000310 isoleucine Drugs 0.000 claims abstract description 31
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 31
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 29
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 25
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 25
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 25
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004220 glutamic acid Substances 0.000 claims abstract description 25
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 25
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 24
- 229930182817 methionine Natural products 0.000 claims abstract description 24
- -1 argiine Chemical compound 0.000 claims abstract description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 17
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 16
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 16
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004474 valine Substances 0.000 claims abstract description 6
- 239000004475 Arginine Substances 0.000 claims description 32
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 32
- 235000009697 arginine Nutrition 0.000 claims description 32
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 10
- 239000011574 phosphorus Substances 0.000 claims description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 8
- XQJHRCVXRAJIDY-UHFFFAOYSA-N aminophosphine Chemical compound PN XQJHRCVXRAJIDY-UHFFFAOYSA-N 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000000577 adipose tissue Anatomy 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 230000009182 swimming Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 9
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 230000007659 motor function Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 241000256856 Vespidae Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 2
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- AJYLWDRNNNHBEV-UHFFFAOYSA-N 2-hydrazinylbutanoic acid Chemical compound CCC(NN)C(O)=O AJYLWDRNNNHBEV-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- JKPAIQYTAZUMKI-UHFFFAOYSA-N N[P] Chemical compound N[P] JKPAIQYTAZUMKI-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002394 glycogenic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to an amino acid composition obtained from the knowledge of a composition composed of amino acids contained in saliva secreted by hornets of the hornet (Vespa genus), and more particularly, to blood associated with intense exercise. It compensates for the decrease in medium amino acids, improves motor function, reduces fatigue after exercise, and recovers from fatigue.In addition, it promotes the process of using body fat for kinetic energy under anaerobic exercise under heavy load.
- the present invention relates to an amino acid composition having an effect of improving blood pressure and a replacement fluid containing the same. Background art
- Non-Patent Document 1 The present inventors have studied the saliva secreted by various hornet larvae, and found that the hornet nutrient solution suppresses the generation of fatigue substances during exercise, prevents a decrease in blood glucose level, and further improves exercise performance.
- Patent Document 1 Furthermore, it has been clarified that the mechanism of action is a function of promoting utilization of fat as energy during exercise (Non-Patent Document 1).
- VAAM Vespa Amino Acid Mixture
- has been suggested to have various effects such as recovery from fatigue accompanying exercise in addition to the above-mentioned effects Patent Documents 2 to 5).
- Non-Patent Document 2 the amino acid balance in blood is greatly disrupted by exercise fatigue. This is thought to be the result of wear and destruction of body tissue due to the stress associated with exercise. However, to date, no attention has been paid to its physiological significance and significance.
- the present inventor further studied the blood amino acid concentration after exercise and the amino acid composition of VAAM, and found that the amino acid composition of VAAM showed an extremely high correlation with the blood amino acid that was reduced by fatigue due to exercise. Was. In other words, decrease due to exhaustion It was found that the more intense amino acids are contained in VA AM. Therefore, it is considered that supplementation of these amino acids is indispensable for improvement of motor function and improvement of fatigue (Patent Document 6).
- trehalose has been shown to significantly increase the concentration of non-esterified fatty acids (NEFA) in mouse serum during exercise (Patent Document 7).
- NEFA non-esterified fatty acids
- the nutrient solution of a hornet contains a considerable amount of trehalose (Non-Patent Document 3). Therefore, they found that when trehalose and VAAM were administered simultaneously, a stronger motor function could be further improved (Patent Document 8).
- VAAM has the function of promoting the process of using body fat for kinetic energy during aerobic endurance exercise.
- this effect is very effective for long-time exercise such as marathon, but may not always be effective for short-time heavy exercise load. Therefore, there is a strong demand for a more effective amino acid mixture for short-time heavy exercise.
- Patent Document 1 Patent No. 2518692
- Patent Document 3 JP-A-4-112825
- Patent Document 4 JP-A-6-336426
- Patent Document 5 JP-A-6-336432
- Patent Document 6 JP-A-9-249556 (US-BA-6224861, EP-B1-873754)
- Patent Document 7 JP-A-5-186353
- Patent document 8 JP 2000-72669 (US-BA-6287757, EP-A1-983726)
- Non-patent document 1 Abe et al., Jap. J. Physical Fitness & Sports Med. 44, 225 (1995)
- Non-patent document 2 T. Bazzarre et al. J. Am. Collage Nutr. 11, 531 (1992)
- Non-Patent Document 3 Abe et al., Comp. Biochem. Physiol. 99C, 79 (1991) Disclosure of the invention
- an object of the present invention is to improve the function of promoting the process of utilizing body fat for kinetic energy under anoxic exercise accompanied by heavy load, which is not necessarily sufficient in an amino acid composition such as VAAM. It is to provide an amino acid composition having the following.
- Another object of the present invention is to provide an amino acid composition that suppresses an increase in lactic acid level due to anoxic exercise as much as possible while maintaining the motor function improving action of VAAM as much as possible.
- Still another object of the present invention is to provide a replacement fluid containing the above amino acid composition.
- the present invention provides the following amino acid composition and replacement fluid.
- Amino acid composition consisting of alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, fenylalanine, proline, serine, threonine, tryptophan, tyrosine, nolin, and glutamine. .
- An amino acid composition comprising alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, fenylalanine, proline, serine, threonine, tyrosine, valine, and glutamine.
- Amino acid consisting of alanine, arginine, glutamic acid, glycine, histidine, iso-isocyanate, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, NO, 'phosphine, and glutamine Acid composition.
- Amino acid consisting of alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, fenylalanine, proline, serine, threonine, tryptophan, tyrosine, amino, phosphine, and glutamine. Composition.
- An amino acid composition comprising alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, norin, and glutamine.
- An amino acid composition comprising zonin, tributofan, tyrosine, amino, phosphorus, and glutamine.
- FIG. 1 is a drawing showing the results of orally administering GVAAM, GCAAMs VAAM or CAAM to mice, and applying a load of 0.3 g to swim.
- FIG. 2 is a drawing showing the results of orally administering GVAAM or VAAM to a mouse, applying a load of 0.3 g, and swimming.
- FIG. 3 is a drawing showing the results of orally administering GVAAM or VAAM to a mouse, applying a load of 0.47 g and swimming.
- Fig. 4 is a drawing showing the free fatty acid value (NEFA value) after GVAAM or VAAM was orally administered to mice, and a 0.47 g load was given to swim. * Indicates that there is a significant difference (p ⁇ 0.05).
- FIG. 5 is a drawing showing blood lactate levels after GVAAM or VAAM was orally administered to mice, and a 0.47 g load was applied to swim.
- FIG. 6 is a drawing showing the blood glucose level (glucose) after GVAAM or VAAM was orally administered to mice, and the mice were allowed to swim with a load of 0.447 g. * Indicates that there is a significant difference (p ⁇ 0.05).
- VAAM has a function to comprehensively activate various physical functions required during exercise.
- the missing function of VAAM is to improve anaerobic exercise with heavy load. Therefore, the amino acid mixture was devised so that the increase in lactic acid level due to anoxic exercise was suppressed as much as possible while maintaining the motor function improving effect of VAAM as much as possible.
- a stronger exercise load swipe or instantaneous exercise
- an amino acid composition that could respond to anoxic exercise as much as possible was examined.
- the basic amino acid composition used in the present invention is a yarn composition as described in Patent Documents 1 to 8 and Non-Patent Documents 1 to 3, and VAAM is particularly preferred.
- Glutamine is added in an amount of 0.01 to 20 mol, preferably 1.0 to 15 mol, and more preferably 2.0 to 10 mol per 100 mol of the basic amino acid composition. If the amount of glumin is less than 0.01 mol, the effect of the addition is not sufficient, and if it exceeds 20 mol, there is a problem that the blood lactate level increases.
- Trehalose may be added to the amino acid composition of the present invention as shown in Patent Document 8.
- Trehalose added to the amino acid composition of the present invention is preferably 0.45 to 1.6: 0.5 to 5.0, more preferably 0.8 to 1 in a mass ratio of the amino acid composition to trehalose. .6: 1.0 to 4.0.
- the amino acid composition of the present invention comprises, in addition to the above amino acids, taurine (Tau) (preferably 3 mol% or less), ethanolamine phosphate (P-EtAm) (preferably 2 mol% or less), cystine (Cys) ( Preferably 0.5 mol% or less, ⁇ -alanine (?
- amino acid in the amino acid composition used in the present invention is particularly preferably an L-amino acid.
- the above-mentioned commercially available amisoic acid may be mixed at the above-mentioned predetermined ratio. When used as a replacement fluid, it may be dissolved in distilled water. Usually, the composition is prepared by mixing the powder in a uniform manner and dissolving it in distilled water when necessary.
- the temperature for producing and storing the composition of the present invention is not particularly limited, but it is preferable to produce and store the composition at room temperature or lower.
- the compositions of the present invention exhibits a weak bitter taste, mice without express no toxicity even 2 O g / kg when administered orally, LD 50 is much exceed the 2 O g / kg.
- the composition of the present invention is useful as a food such as a medicine or a beverage.
- the form of administration when used as a medicament is not particularly limited, but can be via a common administration route such as oral administration, rectal administration, injection, or administration by infusion.
- oral administration it may be used as a composition having the above composition, or as a formulation such as a key, capsule, powder, troche, syrup and the like together with a pharmaceutically acceptable carrier and excipient.
- solid preparations such as tablets and powders, it may take time to absorb. Therefore, oral administration by a liquid preparation or the like is preferable.
- aqueous solution it is preferable to administer as an aqueous solution together with an appropriate additive, for example, salts such as sodium chloride, a buffer, a chelating agent and the like.
- an appropriate additive for example, salts such as sodium chloride, a buffer, a chelating agent and the like.
- an appropriate additive for example, salts such as sodium chloride, a buffer, a chelating agent and the like.
- buffers and isotonic agents dissolve in sterile distilled water.
- intravenous drip infusion may be performed using such a solution.
- drinks such as soft drinks and powdered drinks, with an appropriate flavor, are encapsulated with powders prepared by spray-drying, freeze-drying, micro-fine powder, etc. It can be in the form of an agent.
- compositions of the present invention have very low toxicity, and the dosage can be very widely varied.
- the dosage varies depending on the method of administration and the purpose of use.
- the solid content of the composition is 1 to 1 g / L, 3 to 18 g / day, preferably 2 to 1 g / day. 4 g, daily dose 6 to 12 g.
- 200 to 500 ml of a 0.8 to 3.8% by mass solution per day is used. It may be administered up to three times.
- 100 to 400 ml, preferably 150 to 300 ml may be administered as a 0.8 to 3.8 mass% solution at a time.
- mice 12 to 16 hours of fasted mice ddY (6.8 weeks of age) were orally administered with various amino acid nutrients per 37.5 ⁇ 1 / g body weight, allowed to stand for 30 minutes, and then run at 35 ° C We did swimming exercise in pool. In the case of load swimming, a 0.3 g or 0.447 g weight was attached to the tail. At the time of blood metabolite analysis, 30 minutes after swimming, the mice were immediately bled.
- GVAAM with the following amino acid composition and VAAM, CAAM (Casein amino acid mixture) and GCAAM were used for the positive control.
- VAAM amino acid composition
- CAAM Cyasein amino acid mixture
- GCAAM GCAAM
- Lactate + NAD Lactate Dehydrogenase Pyruvate + NADH
- the PCA-treated supernatant was used and measured by the following Hexokinase method.
- the generated NADPH was measured in the 0D280 circle.
- V AAM conventionally improves the overall endurance function performed by aerobic respiration. Therefore, in order to perform anoxic breathing exercise, a mouse was used to load a weight on the tail during swimming exercise, and the weight was changed to increase the rate of anaerobic exercise. At a load of 0.3 g, four amino acid nutrient solutions, VAAM + glutamine (GVAAM), CAAM + glutamine (GCAAM), VAAM and CAAM, were orally administered, and forced swimming was performed. As a result, the GVAAM group was able to swim for the longest time, followed by the VAAM group, then the GCAM group, and then the CAAM (Fig. 1).
- the load during swimming was further increased to 0.47 g, and a comparison was made between the two.
- the GVAAM group performed a long-term swimming significantly as well as the light load (Fig. 3). .
- amino acid composition GVAAM promotes the improvement of exercise ability as compared to VAAM as the exercise load increases and the ratio of anaerobic breathing exercise increases.
- VAAM has promoted the burning of fat during aerobic endurance exercise, reduced the rise of fatigue substances, and also reduced blood glucose levels.
- VAAM promoted the conversion of fat to athletic energy and promoted aerobic endurance exercises such as long-distance running. Therefore, under 0.47 g of heavy swimming exercise, blood biochemicals closely related to motor function
- the free fatty acid value (NEFA value) of GVAAM was significantly lower than that of VAAM (Fig. 4), indicating that VAAM had better fat burning power under heavy load. .
- NEFA value free fatty acid value
- the blood lactate level was lower in the GVAAM group than in the VAAM group (FIG. 5), and the blood glucose level was significantly higher in the GVAAM group than in VAAM (FIG. 6).
- the amino acid composition of the present invention is obtained by adding glutamine, which is a glycogenic amino acid, to an amino acid composition having a strong motor function-enhancing action such as VAAM. Has an even more effective motor function-improving effect, and has a strong promoting effect on the motor function during anoxic breathing.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW093115054A TWI314452B (en) | 2003-05-30 | 2004-05-27 | Amino acid composition and supplemental solution |
AU2004243164A AU2004243164B8 (en) | 2003-05-30 | 2004-05-31 | Amino acid composition and fluid replacement |
CN2004800217817A CN1829504B (zh) | 2003-05-30 | 2004-05-31 | 氨基酸组合物及补液 |
EP04735515.1A EP1629840B1 (en) | 2003-05-30 | 2004-05-31 | Amino acid composition and fluid replacement |
CA2527435A CA2527435C (en) | 2003-05-30 | 2004-05-31 | Amino acid composition and supplementary liquid containing the same |
NZ544158A NZ544158A (en) | 2003-05-30 | 2004-05-31 | Amino acid composition and fluid replacement |
US11/289,383 US8012924B2 (en) | 2003-05-30 | 2005-11-30 | Amino acid composition and supplementary liquid containing the same |
US12/345,003 US8012926B2 (en) | 2003-05-30 | 2008-12-29 | Amino acid composition and supplementary liquid containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-155397 | 2003-05-30 | ||
JP2003155397A JP4528925B2 (ja) | 2003-05-30 | 2003-05-30 | アミノ酸組成物及び補液 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/289,383 Continuation US8012924B2 (en) | 2003-05-30 | 2005-11-30 | Amino acid composition and supplementary liquid containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004105748A1 true WO2004105748A1 (ja) | 2004-12-09 |
Family
ID=33487356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007850 WO2004105748A1 (ja) | 2003-05-30 | 2004-05-31 | アミノ酸組成物及び補液 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8012924B2 (ja) |
EP (1) | EP1629840B1 (ja) |
JP (1) | JP4528925B2 (ja) |
CN (1) | CN1829504B (ja) |
AU (1) | AU2004243164B8 (ja) |
CA (1) | CA2527435C (ja) |
NZ (1) | NZ544158A (ja) |
TW (1) | TWI314452B (ja) |
WO (1) | WO2004105748A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007029730A1 (ja) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | 老人性貧血を防止又は治療するためのアミノ酸組成物 |
WO2007084059A1 (en) * | 2006-01-20 | 2007-07-26 | Bjoerk Inger | A food composition comprising amino acids |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005027898A1 (ja) * | 2003-09-19 | 2007-11-15 | 独立行政法人理化学研究所 | アミノ酸組成物 |
JP4147280B2 (ja) * | 2003-12-16 | 2008-09-10 | 独立行政法人理化学研究所 | グルタミン含有エネルギー付加型アミノ酸組成物又はアミノ酸溶液 |
US20090306208A1 (en) * | 2005-06-27 | 2009-12-10 | Kenjiro Shimada | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
JP5775657B2 (ja) * | 2006-06-13 | 2015-09-09 | 株式会社明治 | アミノ酸組成物を含有する疲労防止剤 |
US20100144815A1 (en) * | 2007-02-28 | 2010-06-10 | Hiroshi Tsuchita | Amino acid composition |
JP2008247896A (ja) * | 2007-03-07 | 2008-10-16 | Shizuokaken Koritsu Daigaku Hojin | 透析患者用経口アミノ酸組成物 |
EP2135604A4 (en) * | 2007-03-26 | 2011-08-03 | Hirofumi Matsui | PREPARATION OF INFUSION FOR PATIENT SUFFERING FROM CANCER |
US20080268038A1 (en) * | 2007-04-26 | 2008-10-30 | Wolfe Robert R | Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength |
US7820618B2 (en) | 2007-10-04 | 2010-10-26 | Northern Innovations and Formulations | Energy status of an individual by enhanced usage of an endogenous fuel source |
WO2009043136A1 (en) * | 2007-10-04 | 2009-04-09 | Multi Formulations Ltd. | Improving the energy status of an individual by enhanced usage of an endogenous fuel source |
CN104922115A (zh) * | 2007-10-31 | 2015-09-23 | 株式会社明治 | 含有氨基酸组合物的抗疲劳剂 |
EP2095728B1 (en) | 2008-01-25 | 2011-09-07 | Cesar Gallia s.r.l. | Amino acid concentrate in aqueous gel and fatigue-relieving drink obtainable by diluting said concentrate in water |
JPWO2010041647A1 (ja) * | 2008-10-06 | 2012-03-08 | 株式会社明治 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
CN102488685B (zh) * | 2011-12-30 | 2013-05-01 | 贵州扬生医用器材有限公司 | 含复方氨基酸成分的脂质体制剂的应用方法 |
JP5938219B2 (ja) * | 2012-01-23 | 2016-06-22 | 株式会社明治 | 胃排出遅延のための食品用の剤または医療用の剤 |
CN102613653A (zh) * | 2012-04-17 | 2012-08-01 | 安吉东来药用辅料有限责任公司 | 一种含γ-氨基丁酸的营养素饮料及其制备方法 |
JP2016102064A (ja) * | 2013-08-14 | 2016-06-02 | 株式会社明治 | 脂質代謝促進剤 |
JP6496599B2 (ja) * | 2014-06-13 | 2019-04-03 | 花王株式会社 | 筋タンパク質合成シグナル活性化剤 |
EP3685682B1 (en) * | 2014-11-19 | 2023-06-07 | Kalmarna Limited | Oral rehydration composition |
US9937146B2 (en) | 2016-03-23 | 2018-04-10 | Bioadatp, Llc | Enkephalin-influencing composition and method |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN109381460B (zh) * | 2017-08-09 | 2023-09-01 | 湖北一半天制药有限公司 | 一种含18种氨基酸的药物组合物及其制备方法 |
CN109381459B (zh) * | 2017-08-09 | 2023-09-01 | 湖北一半天制药有限公司 | 一种含10种氨基酸的药物组合物及其制备方法 |
KR20200039748A (ko) | 2017-08-14 | 2020-04-16 | 악셀라 헬스 인크. | 간 질환 치료를 위한 아미노산 조성물 |
CA3084319A1 (en) * | 2017-12-11 | 2019-06-20 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US11666639B2 (en) * | 2019-06-03 | 2023-06-06 | Societe Des Produits Nestle S.A. | Recovery dietary supplement |
WO2021178860A1 (en) * | 2020-03-06 | 2021-09-10 | Axcella Health Inc. | Amino acid compositions and methods for muscle and myotube modulation |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500775A (ja) * | 1987-10-29 | 1991-02-21 | アクチエボラゲット、エリック、ビナルス | 非経口栄養サポート用アミノ酸組成物 |
JPH0495065A (ja) * | 1990-08-10 | 1992-03-27 | Kissei Pharmaceut Co Ltd | アリールチオアルキルカルボン酸誘導体 |
JPH04112825A (ja) * | 1990-09-03 | 1992-04-14 | Rikagaku Kenkyusho | 脂質代謝調節剤 |
JPH0558889A (ja) * | 1991-08-27 | 1993-03-09 | Otsuka Pharmaceut Factory Inc | 脂肪アミノ酸粉末及び粉末栄養組成物 |
JPH08502039A (ja) * | 1992-07-17 | 1996-03-05 | ブリガム・アンド・ウイメンズ・ホスピタル | 筋肉の劣化を減少させるための組成物および方法 |
JPH0873351A (ja) * | 1994-06-30 | 1996-03-19 | Ajinomoto Co Inc | 炎症性腸疾患用栄養組成物 |
JPH0952828A (ja) * | 1995-08-10 | 1997-02-25 | Sasaki Kagaku Kogyo Kk | アミノ酸組成剤およびその使用方法 |
JPH09294565A (ja) * | 1996-04-26 | 1997-11-18 | Shimizu Seiyaku Kk | グルタミン含有栄養液 |
JPH11302163A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
JPH11302164A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719119A (en) * | 1985-12-18 | 1998-02-17 | British Technology Group, Ltd. | Parenteral nutrition therapy with amino acids |
US5310768A (en) * | 1987-10-29 | 1994-05-10 | Ab Erik Vinnars | Method for improving the glutamine content in skeletal muscle and composition therefore |
JP2518692B2 (ja) * | 1989-06-14 | 1996-07-24 | 理化学研究所 | 筋力持続剤,滋養強壮剤,輸液用剤,栄養補給剤,疲労回復剤及び乳酸生成調節剤 |
EP0507872B1 (en) * | 1989-12-29 | 2000-04-26 | B. Braun Medical Inc. | The use of arginine as an immunostimulator |
JP2873493B2 (ja) | 1990-08-09 | 1999-03-24 | 理化学研究所 | 血糖調節剤 |
JPH05186533A (ja) | 1991-04-03 | 1993-07-27 | Denki Kagaku Kogyo Kk | 無水マレイン酸−アルキルビニルエーテル共重合体の製造法 |
JP3029902B2 (ja) | 1991-11-13 | 2000-04-10 | 新日本製鐵株式会社 | 血清脂質増加剤 |
JP4009682B2 (ja) | 1993-05-28 | 2007-11-21 | 独立行政法人理化学研究所 | アドレナリン及びノルアドレナリン分泌促進組成物 |
JP3553992B2 (ja) | 1993-05-28 | 2004-08-11 | 独立行政法人理化学研究所 | 代謝調節剤 |
CH687379A5 (de) | 1993-09-03 | 1996-11-29 | Sig Schweiz Industrieges | Uebergangseinrichtung zwischen zwei gekuppelten Fahrzeugen. |
EP0689835A3 (en) | 1994-06-30 | 1996-04-17 | Ajinomoto Kk | Composition containing an amino acid mixture and at least one N-3 fatty acid |
US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
JP2518692Y2 (ja) | 1994-12-29 | 1996-11-27 | 第一衛材株式会社 | 廃油回収容器 |
TW413633B (en) | 1996-01-09 | 2000-12-01 | Rikagaku Kenkyusho | Amino acid composition |
JP2000072669A (ja) | 1998-08-24 | 2000-03-07 | Inst Of Physical & Chemical Res | アミノ酸・糖組成物 |
US6511696B2 (en) * | 2000-12-13 | 2003-01-28 | Novartis Nutrition Ag | Infant formula with free amino acids and nucleotides |
-
2003
- 2003-05-30 JP JP2003155397A patent/JP4528925B2/ja not_active Expired - Lifetime
-
2004
- 2004-05-27 TW TW093115054A patent/TWI314452B/zh active
- 2004-05-31 CN CN2004800217817A patent/CN1829504B/zh not_active Expired - Lifetime
- 2004-05-31 AU AU2004243164A patent/AU2004243164B8/en not_active Ceased
- 2004-05-31 NZ NZ544158A patent/NZ544158A/en unknown
- 2004-05-31 WO PCT/JP2004/007850 patent/WO2004105748A1/ja active Application Filing
- 2004-05-31 CA CA2527435A patent/CA2527435C/en not_active Expired - Lifetime
- 2004-05-31 EP EP04735515.1A patent/EP1629840B1/en not_active Expired - Lifetime
-
2005
- 2005-11-30 US US11/289,383 patent/US8012924B2/en not_active Expired - Fee Related
-
2008
- 2008-12-29 US US12/345,003 patent/US8012926B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500775A (ja) * | 1987-10-29 | 1991-02-21 | アクチエボラゲット、エリック、ビナルス | 非経口栄養サポート用アミノ酸組成物 |
JPH0495065A (ja) * | 1990-08-10 | 1992-03-27 | Kissei Pharmaceut Co Ltd | アリールチオアルキルカルボン酸誘導体 |
JPH04112825A (ja) * | 1990-09-03 | 1992-04-14 | Rikagaku Kenkyusho | 脂質代謝調節剤 |
JPH0558889A (ja) * | 1991-08-27 | 1993-03-09 | Otsuka Pharmaceut Factory Inc | 脂肪アミノ酸粉末及び粉末栄養組成物 |
JPH08502039A (ja) * | 1992-07-17 | 1996-03-05 | ブリガム・アンド・ウイメンズ・ホスピタル | 筋肉の劣化を減少させるための組成物および方法 |
JPH0873351A (ja) * | 1994-06-30 | 1996-03-19 | Ajinomoto Co Inc | 炎症性腸疾患用栄養組成物 |
JPH0952828A (ja) * | 1995-08-10 | 1997-02-25 | Sasaki Kagaku Kogyo Kk | アミノ酸組成剤およびその使用方法 |
JPH09294565A (ja) * | 1996-04-26 | 1997-11-18 | Shimizu Seiyaku Kk | グルタミン含有栄養液 |
JPH11302163A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
JPH11302164A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1629840A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007029730A1 (ja) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | 老人性貧血を防止又は治療するためのアミノ酸組成物 |
JP5220415B2 (ja) * | 2005-09-06 | 2013-06-26 | 株式会社明治 | 老人性貧血を防止又は治療するためのアミノ酸組成物 |
WO2007084059A1 (en) * | 2006-01-20 | 2007-07-26 | Bjoerk Inger | A food composition comprising amino acids |
Also Published As
Publication number | Publication date |
---|---|
CN1829504A (zh) | 2006-09-06 |
US20060079565A1 (en) | 2006-04-13 |
EP1629840A4 (en) | 2007-01-10 |
AU2004243164B8 (en) | 2010-10-21 |
JP4528925B2 (ja) | 2010-08-25 |
EP1629840A1 (en) | 2006-03-01 |
CA2527435A1 (en) | 2004-12-09 |
EP1629840B1 (en) | 2017-08-16 |
US8012926B2 (en) | 2011-09-06 |
US20090117208A1 (en) | 2009-05-07 |
US8012924B2 (en) | 2011-09-06 |
AU2004243164B2 (en) | 2010-09-23 |
AU2004243164A1 (en) | 2004-12-09 |
TWI314452B (en) | 2009-09-11 |
CN1829504B (zh) | 2010-12-08 |
NZ544158A (en) | 2009-01-31 |
TW200509899A (en) | 2005-03-16 |
JP2004352696A (ja) | 2004-12-16 |
CA2527435C (en) | 2012-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004105748A1 (ja) | アミノ酸組成物及び補液 | |
JP2000072669A (ja) | アミノ酸・糖組成物 | |
WO1997025060A1 (fr) | Compositions d'acides amines | |
JP2873497B2 (ja) | 脂質代謝調節剤 | |
HUE032486T2 (en) | An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB) | |
JPH03128318A (ja) | 筋力持続剤,滋養強壮剤,輸液用剤,栄養補給剤,疲労回復剤及び乳酸生成調節剤 | |
JP3814683B2 (ja) | アミノ酸組成物 | |
WO2010041647A1 (ja) | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 | |
US6506552B2 (en) | Amino acid-trehalose composition | |
US20080161380A1 (en) | Amino acid composition | |
JPH06336426A (ja) | 代謝調節剤 | |
JP4147280B2 (ja) | グルタミン含有エネルギー付加型アミノ酸組成物又はアミノ酸溶液 | |
JP6423717B2 (ja) | 非糖質性エネルギー産生増強剤 | |
DiMenna et al. | cost 2 Acute l-arginine supplementation reduces the O |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480021781.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2527435 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11289383 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004243164 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2004735515 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004735515 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544158 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004243164 Country of ref document: AU Date of ref document: 20040531 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004243164 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004735515 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11289383 Country of ref document: US |